Who are RBC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FFP and Cryoprecipitate, Fresh frozen plasma, Dry plasma, Pathogen-Reduced Cryoprecipitate, Pathogen-Reduced Plasma, Humanalbumin 5%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rbc.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RBC — Competitive Intelligence Brief

RBC (RBC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Blood product. Area: Oncology, Hematology.

marketed Blood product Oncology, Hematology Small molecule Live · refreshed every 30 min

Target snapshot

RBC (RBC) — Asan Medical Center. Red blood cell transfusion is used to increase the number of red blood cells in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
RBC TARGET	RBC	Asan Medical Center	marketed	Blood product
FFP and Cryoprecipitate	FFP and Cryoprecipitate	The University of Texas Health Science Center, Houston	marketed	Blood product / Hemostatic agent
Fresh frozen plasma	Fresh frozen plasma	Rigshospitalet, Denmark	marketed	Blood product / Plasma derivative
Dry plasma	Dry plasma	Vastra Gotaland Region	marketed	Blood product / Plasma derivative
Pathogen-Reduced Cryoprecipitate	Pathogen-Reduced Cryoprecipitate	Weill Medical College of Cornell University	marketed	Blood product / Hemostatic agent
Pathogen-Reduced Plasma	Pathogen-Reduced Plasma	Coalition for National Trauma Research	marketed	Blood product / Plasma derivative
Humanalbumin 5%	Humanalbumin 5%	Medical University of Vienna	marketed	Plasma volume expander; blood product derivative

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Blood product class)

Asan Medical Center · 1 drug in this class
Johns Hopkins University · 1 drug in this class
Technische Universität Dresden · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RBC — Competitive Intelligence Brief. https://druglandscape.com/ci/rbc. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab